GeneHealth - Your precision medicine

Ovarian Hyperstimulation Syndrome

Disease Details

Family Health Simplified

Buy Membership

Description: Ovarian hyperstimulation syndrome (OHSS) is a medical condition where the ovaries swell and become painful due to an exaggerated response to hormonal fertility treatments, leading to fluid leakage into the abdomen and chest.
Type: Ovarian Hyperstimulation Syndrome (OHSS) is not classified as a genetically transmitted condition. It typically occurs as a complication of ovarian stimulation treatments used in assisted reproductive technologies, such as in vitro fertilization (IVF).
Signs And Symptoms: Symptoms are set into three categories: mild, moderate, and severe. Mild symptoms include abdominal bloating and feeling of fullness, nausea, diarrhea, and slight weight gain. Moderate symptoms include excessive weight gain (weight gain of greater than 2 pounds per day), increased abdominal girth, vomiting, diarrhea, darker urine, decreased urine output, excessive thirst, and skin and/or hair feeling dry (in addition to mild symptoms). Severe symptoms are fullness/bloating above the waist, shortness of breath, pleural effusion, urination significantly darker or has ceased, calf and chest pains, marked abdominal bloating or distention, and lower abdominal pains (in addition to mild and moderate symptoms).
Prognosis: Ovarian hyperstimulation syndrome (OHSS) prognosis depends on the severity. In mild to moderate cases, symptoms typically resolve on their own with conservative management and self-care, leading to a good overall prognosis. Severe cases may require hospitalization and intensive care, but with timely treatment, most patients recover fully. Long-term complications are rare but can include ovarian torsion and thromboembolic events.
Onset: Ovarian hyperstimulation syndrome (OHSS) typically presents within a week of ovulation or egg retrieval, especially when fertility medications have been used to stimulate the ovaries. In some cases, late-onset OHSS can occur, typically 10-17 days after ovulation or egg retrieval, often due to the production of pregnancy-related hormones.
Prevalence: The exact prevalence of ovarian hyperstimulation syndrome (OHSS) is variable and not precisely known, but it generally occurs in about 0.6% to 5% of women undergoing fertility treatments such as in vitro fertilization (IVF).
Epidemiology: Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic complication primarily associated with assisted reproductive technologies, such as in vitro fertilization (IVF). The incidence of OHSS can vary widely depending on the population and treatment protocols. Mild cases occur in approximately 20-33% of IVF cycles, while moderate to severe OHSS occurs in 3-8% of cycles. Severe OHSS is less common, affecting about 0.1-2% of women undergoing such treatments. It is more prevalent in women with polycystic ovary syndrome (PCOS), younger women, those with a high number of developing follicles, and higher serum estradiol levels.
Intractability: Ovarian hyperstimulation syndrome (OHSS) is not generally considered intractable. OHSS is a condition that can occur in women undergoing fertility treatments, particularly those involving hormonal stimulation of the ovaries. The severity of OHSS can range from mild to severe. Mild and moderate cases are often manageable with supportive care, hydration, and monitoring, while severe cases may require hospitalization and more intensive treatment. Early detection and careful management by healthcare providers can significantly reduce the risks and complications associated with OHSS.
Disease Severity: Ovarian Hyperstimulation Syndrome (OHSS) is a complication that can arise during in vitro fertilization (IVF) treatments, particularly when fertility medications are used to induce ovulation.

**Disease Severity:**
OHSS can vary in severity, typically categorized as mild, moderate, or severe.
- **Mild OHSS:** Symptoms might include abdominal bloating, mild pain, and mild gastrointestinal symptoms.
- **Moderate OHSS:** In addition to the symptoms of mild OHSS, there may be more significant abdominal pain, nausea, vomiting, and diarrhea.
- **Severe OHSS:** This form can include rapid weight gain, intense abdominal pain, severe nausea and vomiting, shortness of breath, reduced urination, and fluid accumulation in the abdomen and chest.

In rare cases, severe OHSS can lead to serious complications such as blood clots, kidney failure, and ovarian torsion, which is a medical emergency. It requires prompt medical attention.
Healthcare Professionals: Disease Ontology ID - DOID:5425
Pathophysiology: OHSS has been characterized by the presence of multiple luteinized cysts within the ovaries leading to ovarian enlargement and secondary complications, but that definition includes almost all women undergoing ovarian stimulation. The central feature of clinically significant OHSS is the development of vascular hyperpermeability and the resulting shift of fluids into the third space.As hCG causes the ovary to undergo extensive luteinization, large amounts of estrogens, progesterone, and local cytokines are released. It is almost certain that vascular endothelial growth factor (VEGF) is a key substance that induces vascular hyperpermeability, making local capillaries "leaky", leading to a shift of fluids from the intravascular system to the abdominal and pleural cavity. Supraphysiologic production of VEGF from many follicles under the prolonged effect of hCG appears to be the specific key process underlying OHSS. Thus, while the woman accumulates fluid in the third space, primarily in the form of ascites, she actually becomes hypovolemic and is at risk for respiratory, circulatory (such as arterial thromboembolism since blood is now thicker), and renal problems. Women who are pregnant sustain the ovarian luteinization process through the production of hCG.Avoiding OHSS typically requires interrupting the pathological sequence, such as avoiding the use of hCG. One alternative is to use a GnRH agonist instead of hCG. While this has been repeatedly shown to "virtually eliminate" OHSS risk, there is some controversy regarding the effect on pregnancy rates if a fresh non-donor embryo transfer is attempted, almost certainly due to a luteal phase defect. There is no dispute that the GnRH agonist trigger is effective for oocyte donors and for embryo banking (cryopreservation) cycles.
Carrier Status: Ovarian Hyperstimulation Syndrome (OHSS) is not inherited, so the concept of carrier status does not apply.
Mechanism: Ovarian Hyperstimulation Syndrome (OHSS) is a complication often associated with assisted reproductive technologies like in vitro fertilization (IVF).

**Mechanism:**
OHSS results from the overstimulation of the ovaries due to excessive follicular response to gonadotropins, leading to enlarged ovaries and increased vascular permeability. This causes fluid to shift from the vascular compartment to the extravascular space, leading to ascites (fluid in the abdomen), pleural effusion, and other systemic symptoms.

**Molecular Mechanisms:**
1. **Vasoactive Mediators:** The primary molecular mechanism involves the excessive production of vasoactive substances, particularly vascular endothelial growth factor (VEGF). VEGF increases vascular permeability, promoting fluid leakage from the capillaries.
2. **Cytokines and Inflammatory Mediators:** Other mediators include interleukins (IL), prostaglandins, and endothelin, which contribute to the inflammatory response and vascular changes.
3. **Activation of the Renin-Angiotensin System (RAS):** The RAS is also implicated, where increased angiotensin II levels exacerbate vascular permeability.
4. **HCG Triggering Ovulation:** Human chorionic gonadotropin (hCG), used to trigger ovulation, plays a critical role by enhancing VEGF expression, further amplifying the cascade of events leading to OHSS.

Understanding these mechanisms is vital for developing targeted therapies to manage or prevent OHSS.
Treatment: Treatment of OHSS depends on the severity of the hyperstimulation.
Mild OHSS can be treated conservatively with monitoring of abdominal girth, weight, and discomfort on an outpatient basis until either conception or menstruation occurs. Conception can cause mild OHSS to worsen in severity.Moderate OHSS is treated with bed rest, fluids, and close monitoring of labs such as electrolytes and blood counts. Ultrasound may be used to monitor the size of ovarian follicles. Depending on the situation, a physician may closely monitor a women's fluid intake and output on an outpatient basis, looking for increased discrepancy in fluid balance (over 1 liter discrepancy is cause for concern). Resolution of the syndrome is measured by decreasing size of the follicular cysts on 2 consecutive ultrasounds.Aspiration of accumulated fluid (ascites) from the abdominal/pleural cavity may be necessary, as well as opioids for the pain. If the OHSS develops within an IVF protocol, it can be prudent to postpone transfer of the pre-embryos since establishment of pregnancy can lengthen the recovery time or contribute to a more severe course. Over time, if carefully monitored, the condition will naturally reverse to normal – so treatment is typically supportive, although a woman may need to be treated or hospitalized for pain, paracentesis, and/or intravenous hydration.
Compassionate Use Treatment: Ovarian hyperstimulation syndrome (OHSS) typically occurs as a result of fertility treatments, especially those involving medications to stimulate the ovaries. While standard treatments mainly focus on symptom management and supportive care, there are some off-label or experimental approaches worth noting:

1. **Dopamine Agonists (e.g., Cabergoline)**: Although primarily used for other indications such as prolactinomas, dopamine agonists have been explored off-label to reduce vascular permeability in OHSS cases. Their usage is based on the idea that they can inhibit the action of vascular endothelial growth factor (VEGF), which plays a key role in OHSS pathophysiology.

2. **Intravenous Albumin**: This is sometimes used off-label to manage severe OHSS. Albumin infusion can help maintain intravascular volume and prevent fluid shift into the third space, although its efficacy is still under study.

3. **GnRH Antagonists**: These can be employed as a preventive measure to reduce the risk of OHSS by controlling the ovarian response to stimulation. This use is gaining acceptance but might still be considered experimental in some settings.

4. **Calcium Infusions**: Some experimental protocols suggest the use of intravenous calcium to mitigate symptoms, though robust evidence supporting this approach is limited.

5. **Low Molecular Weight Heparin (LMWH)**: As an off-label approach, LMWH may be considered for prophylaxis in women with a high risk of thromboembolic events due to OHSS, but more research is needed to validate its widespread use.

These treatments are often considered in cases where conventional management strategies are insufficient or when patients exhibit severe symptomatic manifestations. It's important for clinicians to weigh the risks and benefits of such approaches and to consider individual patient circumstances.
Lifestyle Recommendations: For Ovarian Hyperstimulation Syndrome (OHSS), lifestyle recommendations primarily focus on symptom management and prevention of complications:

1. **Stay Hydrated**: Drink plenty of fluids, especially electrolyte solutions, to prevent dehydration.
2. **Avoid Strenuous Activities**: Refrain from vigorous physical activities that could exacerbate symptoms or increase the risk of ovarian torsion.
3. **Balanced Diet**: Eat a balanced diet rich in protein and low in sodium to manage symptoms and fluid balance.
4. **Monitor Symptoms**: Keep track of any changes in symptoms and report severe or worsening symptoms to your healthcare provider immediately.
5. **Rest**: Ensure adequate rest to help the body recover.
6. **Avoid Alcohol and Caffeine**: These can worsen dehydration and other symptoms.

Always follow the guidance of your healthcare provider, as they can give personalized recommendations based on the severity of your condition.
Medication: Ovarian hyperstimulation syndrome is particularly associated with injection of a hormone called human chorionic gonadotropin (hCG) which is used for inducing final oocyte maturation and/or triggering oocyte release. The risk is further increased by multiple doses of hCG after ovulation and if the procedure results in pregnancy.Using a GnRH agonist instead of hCG for inducing final oocyte maturation and/or release results in an elimination of the risk of ovarian hyperstimulation syndrome, but a slight decrease of the delivery rate of approximately 6%.
Repurposable Drugs: Ovarian hyperstimulation syndrome (OHSS) can sometimes be managed with medications that are primarily used for other conditions but may have beneficial effects. Repurposable drugs for OHSS include:

1. **Cabergoline**: Originally used for hyperprolactinemia, cabergoline can help reduce the severity of OHSS by inhibiting vascular endothelial growth factor (VEGF).

2. **Metformin**: Commonly used for type 2 diabetes and polycystic ovary syndrome (PCOS), metformin may help reduce the incidence or severity of OHSS in women undergoing fertility treatments.

Note: Always consult a healthcare provider for personalized medical advice.
Metabolites: Ovarian hyperstimulation syndrome (OHSS) is a medical condition that can occur in some women who are undergoing fertility treatment, particularly with medications that stimulate the ovaries. Metabolites generally refer to the small molecules that are intermediates and products of metabolism. In the context of OHSS, the focus is usually more on the hormonal changes and fluid balance rather than specific metabolites. The condition involves increased blood levels of certain hormones like estrogen and hCG (human chorionic gonadotropin), which can lead to an exaggerated response by the ovaries. Understanding these hormonal changes is critical for managing the syndrome effectively.
Nutraceuticals: Nutraceuticals are food-derived products that offer health benefits and are often used to support various medical conditions. There is limited scientific evidence specifically regarding the use of nutraceuticals for the prevention or treatment of Ovarian Hyperstimulation Syndrome (OHSS). Management of OHSS typically focuses on careful monitoring, fluid management, and adjusting hormone protocols during fertility treatments. It’s essential to consult with a healthcare provider before using any supplements or nutraceuticals for OHSS.
Peptides: Ovarian Hyperstimulation Syndrome (OHSS) is not directly related to specific peptides in its pathology or treatment. Instead, it primarily involves hormonal imbalances and fluid shifts often resulting from fertility treatments. Therapy focuses on symptom management, which may involve fluid management, pain relief, and in severe cases, hospitalization. Advanced treatments or research into peptides specific to OHSS is limited or currently not well-defined.